A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: estimated 12 to confirmed 6v11
  2. Study Status, Eligibilityv10
  3. Primary endpoints revised (4)v9 Show 4 more changesShow less
    • Trial status: Terminated to Completed
    • Primary completion date: Apr 2005
    • Study completion date: Dec 2005
    • Eligibility criteria revised
  4. Eligibility criteria revisedv8
  5. Enrollment target: 6 to 12
    • Study site revised
    • Collaborators: 1 to 2
    • Eligibility criteria expanded, about 4 words
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Sponsor's reason: Research cancelled by pharmaceutical company.v5 Show 4 more changesShow less
    • Enrollment target: 6
    • Start date: Apr 2004
    • Eligibility criteria shortened, about 30 words
    • Study title expanded, about 3 words
  3. 3 versions Re-verified since Jun 13, 2006, no change to tracked fieldsv2-v4
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Stanford University
635 trials monitored
See 40 trials at risk
Lung Cancer
4,822 trials monitored
See 269 trials at risk
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
Trial Details
NCT Number NCT00238628
Lead Sponsor Stanford University
Collaborators: Ligand Pharmaceuticals, AstraZeneca
Conditions
(from sponsor)		 Lung Cancer
Related terms Lung Neoplasms
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov